In the absence of a submission from the holder of the marketing authorisation, elvitegravir (Vitekta®), co-administered with ritonavir-boosted protease inhibitor and with other antiretroviral agents, cannot be endorsed for use within NHS Wales for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults who are infected with HIV-1 without known mutations associated with resistance to elvitegravir. This product is currently not marketed in the UK.